WAIVERWaiver • November 14th, 2024 • Panbela Therapeutics, Inc. • Pharmaceutical preparations • Kentucky
This WAIVER (this “Waiver”) is entered into as of October 2, 2024, by and among Panbela Therapeutics, Inc., a Delaware corporation, together with its wholly-owned subsidiary, Cancer Prevention Pharmaceuticals, Inc., with an address of 712 Vista Boulevard, Suite 305, Waconia, Minnesota 55387 (together, the “Borrower”) and USWM, LLC, a Delaware limited liability company with an address of 4441 Springdale Road, Louisville, KY 40324 (the “Lender”). All capitalized terms used but not defined in this Waiver have the meanings assigned to them in the Loan Agreement (as defined below).
SUBORDINATION AGREEMENTSubordination Agreement • November 14th, 2024 • Panbela Therapeutics, Inc. • Pharmaceutical preparations
THIS SUBORDINATION AGREEMENT (“Agreement”) is executed as of the 19th day of August, 2024 (the “Effective Date”), by Michael T. Cullen, a natural person (the “Junior Lender”), and PANBELA THERAPEUTICS, INC., a Delaware corporation (the “Borrower”), in favor and for the benefit of USWM, LLC, a Delaware limited liability company (together with its successors and assigns, the “Lender”).
ContractSubordinated Promissory Note • November 14th, 2024 • Panbela Therapeutics, Inc. • Pharmaceutical preparations • Minnesota
THIS SUBORDINATED PROMISSORY NOTE IS SUBJECT TO THE SUBORDINATION AGREEMENT, DATED AS OF AUGUST 19, 2024, BY AND AMONG BORROWER, NOTEHOLDER AND USWM, LLC (“SUBORDINATION AGREEMENT”), UNDER WHICH THIS SUBORDINATED PROMISSORY NOTE AND THE NOTEHOLDER’S RIGHTS HEREUNDER ARE SUBORDINATED IN THE MATTER SET FORTH THEREIN
